Dupilumab for the treatment of refractory allergic contact dermatitis from rubber/latex concomitant with atopic dermatitis

Koh, Young Gue; Park, Jae Wan; Shin, Sun Hye; Kim, Beom Joon; Yoo, Kwang Ho

doi:10.1111/jdv.18099

Cited by 3 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ACD mechanisms are highly variable and allergen-specific with, e.g., a strong Th1/Th17-polarization found for nickel while fragrances and rubber showed a Th2-bias [ 42 ]. Records found for a total of 67 patients with or without concomitant AD that were refractory to topical and systemic steroids as well as other systemic immunosuppressants and subsequently treated with dupilumab showed complete or partial responses in 65/67 patients ( Table 1 ) [ 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 ]. In two cases, no effects of dupilumab were reported [ 60 , 61 ].…”

Section: Resultsmentioning

confidence: 99%

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2 inflammation. Most recently, dupilumab was approved by the U.S. Food and Drug Administration for prurigo nodularis (PN). Given its relatively good safety profile, effective off-label use of dupilumab has been reported for a multitude of dermatologic diseases and several clinical trials for dermatologic skin conditions are currently ongoing. We conducted a systematic review of applications of dupilumab in dermatology other than AD and PN by searching the databases PubMed/Medline, Scopus, Web of Science and Cochrane Library as well as the clinical trial registry ClinicalTrials.gov. We found several reports for effective treatment of bullous autoimmune diseases, eczema, prurigo, alopecia areata, chronic spontaneous urticaria, Netherton syndrome and a variety of other chronic inflammatory skin diseases.

show abstract